Composition for treatment, alleviation or prophylaxis of acne

A composition, the technology of Propionibacterium acnes, applied in the direction of drug combination, drug delivery, medical preparations containing active ingredients, etc., can solve the problem of pathogenic ribotype treatment methods without skin microbiota regulation of Propionibacterium acnes

Pending Publication Date: 2022-02-11
莱托生物股份有限公司
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A disadvantage of the present invention is that it provides non-specific inhibition of P. acnes (and the natural skin microbiota), whereby the two pathogenic ribotypes of P. acnes (resulting in the development of acne vulgaris); and the non-pathogenic Propionibacterium acnes ribosomal form
[0009] In addition to the negative side effects caused by currently available treatments, there are no treatments targeting the modulation of the skin microbiota and targeting the pathogenic riboform of P. acnes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treatment, alleviation or prophylaxis of acne
  • Composition for treatment, alleviation or prophylaxis of acne
  • Composition for treatment, alleviation or prophylaxis of acne

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0248] Example 1 strain screening and identification

[0249] sample

[0250] In order to identify and select bacterial strains according to the invention, a collection of lactic acid bacteria (LAB) strains was established. Samples from different sources, such as homemade sauerkraut, kimchi, and healthy human donor samples (vaginal, oral, anal, skin) were collected to isolate at least 995 species of lactic acid bacteria. Samples were collected on Man Rogosa Sharp (MRS, Sigma-Aldrich) medium and agar medium, and cultured anaerobically at 37°C overnight or until colonies formed. Isolates were plated and subcultured until pure colonies were obtained. Pure colonies were stored in MRS broth containing 25% glycerol at -80 °C for future use. Strains were identified using standard methods of 16S rRNASanger sequencing.

[0251] Example 2 - Co-aggregation

[0252] P. acnes strains obtained from BEI resources were used as research test organisms for the screening.

[0253]

[02...

example 3

[0275] Example 3 – Effect of pH on Coaggregation.

[0276] Coaggregation was determined according to the known method Cisar, J.O. et al. (1979) as described above.

[0277] All lactic acid bacteria (LAB) inoculum were grown anaerobically overnight in MRS broth, and P. acnes strains were grown anaerobically in BHI broth at 37°C to a cell density of approximately 10 8 CFU / ml (2-3 days). Overnight cell samples were harvested by centrifugation (6000 rpm for 2 minutes) and the supernatant removed from the pellet. The pellets were washed twice separately in the pH adjusted buffer used for the co-aggregation assay.

[0278] MOPS (3-(N-morpholino)propanesulfonic acid) from Merck (product 69947) and MES (2-(N-morpholino)ethanesulfonic acid) buffers from Sigma (product M2933) were used as A concentration of 100 mM was used. MES is used for pH4.5, pH5, pH5.5, pH6 and pH6.5. MOPS is used for pH6.5, pH7, pH7.5 and pH8.

[0279] Slightly less co-aggregation was found in the inert buff...

example 6

[0320] Strains LAB strain LB356R was formulated in vegetable oil containing jojoba oil and almond oil (1:1). to about 10 8 The concentration of CFU / ml oil was added to the strain.

[0321] Ten adolescents (15-19 years old) with acne-prone skin were treated with the composition once a day. Visual assessment of acne severity by pre-treatment ( Figure 1a ) and after treatment ( Figure 1b ) of the picture is OK. Visual improvement was observed in all testers and, on average, improvement was detectable after 3-4 days of treatment.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a composition comprising one or more of bacterial strains, wherein the one or more of bacterial strains exhibit a stronger inhibition of pathogenic C. acnes strains compared to non-pathogenic C. acnes strains.

Description

technical field [0001] The present invention relates to compositions comprising bacterial strains. In particular, the present invention relates to novel topical dermatological compositions comprising bacterial strains for treatment; palliation; inhibition; prophylaxis; and / or prevention of growth of pathogenic microorganisms. Background technique [0002] Acne (acne) is one of the most common and well-established skin diseases, affecting about 90% of the world's population at some stage in their life. The disease is a chronic inflammatory dermatosis of the pilosebaceous glands of the skin with a multifactorial pathogenesis. It usually starts during puberty with hormonal changes and is further exacerbated by genetic factors. [0003] Propionibacterium acnes (formerly Probionibacterium acnes) is a Gram-positive anaerobic bacterium that resides in sebaceous follicles, which are part of the natural flora of the pilosebaceous unit; however, in acne patients Elevated levels of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/744A61K35/747A61P17/10
CPCA61K35/744A61K35/747A61P17/10A61K2035/115A61K9/0014A61K35/741
Inventor C·维德尔K·B·奥尔森S·凯鲁夫
Owner 莱托生物股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap